Obiflex, a doctor-led health programme, has launched monthly instalment plans for prescription GLP-1 weight-loss treatment. A three-month programme costs R1,499 a month over five payments, and a six-month programme costs R1,999 a month over nine payments. Both include a virtual doctor consultation, health coaching, tracking tools and home delivery, all run through WhatsApp or the web.

Obiflex says it is one of the first companies in South Africa to offer buy-now-pay-later on prescription medicine.

The timing follows a regulatory crackdown. On 23 May, SAHPRA and the South African Pharmacy Council announced enforcement action against the unlawful manufacture of unregistered GLP-1 medicines, after inspecting Sentra Pharmacy in Pretoria and seizing all semaglutide and tirzepatide products on site. SAHPRA said the pharmacy was manufacturing under the pretext of compounding, and noted reports of adverse events including hospitalisations.

Obiflex puts the number of South Africans who had been using cheaper compounded versions at as many as 300,000. With that route closed, registered treatment costs R3,000 to R6,000 a month before consultations, and medical schemes typically cover only around half, and only for members with a diabetes diagnosis. Obiflex says the category is worth about R3 billion a year. The programme uses low-dose treatment paired with coaching and targets up to 10% body weight loss over six months.

Co-founder and chief executive Shaun Barns says demand does not disappear when a route is shut down, and without legitimate affordable access it pushes people toward other unregulated sources. The company is backed by investment firm Grovest and has partnered with a large pharmaceutical company it does not name.

TechFinancials carried the launch, including co-founder Dr Riaz Motara's role training the virtual doctor network to address underlying causes of weight change rather than treating prescribing as a standalone transaction. SAHPRA's May statement sets out what inspectors found, including illegally imported ingredients and no testing for identity, potency or purity. MedicalBrief covered the separate patent dispute between Novo Nordisk and the same pharmacy.

Do the arithmetic on the plans. The three-month programme is R7,495 in total, about R2,500 per month of treatment, paid over five months. The six-month programme is R17,991, about R3,000 per month of treatment, paid over nine months. So on both plans you are still paying after the treatment period ends.

That is how instalment finance normally works, and it is disclosed, but it matters for a treatment whose results depend on what happens after you stop. The price is also partly lower because the dose is lower, which is a clinical choice worth understanding rather than a discount.

The business pattern is familiar from this month. When regulators closed the cheap route, demand stayed, and the opportunity moved into financing the gap between what people want and what they can pay, the same logic behind DNI's R500-million device financing bet. It also points to where healthtech is heading here: prescribing, coaching, delivery and payment bundled into one WhatsApp flow. The launch figures and the 300,000 estimate are the company's own.

You might also like our piece on Yellow's Series C for smartphone financing, SA phone contract prices rising twice as fast as the phones, and the first AI-assisted brain tumour operation.

Get more SA tech and business news and subscribe to The Open Letter.